)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Singular Genomics Systems
Singular Genomics Systems (OMIC) investor relations material
Singular Genomics Systems has been acquired
Singular Genomics Systems Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary19 Nov, 2024
Executive summary
Singular Genomics develops next-generation sequencing and multiomics technologies, with the G4 platform available and G4X Spatial Sequencer in development, targeting NGS and spatial biology markets.
Shipped first G4X Early Access instrument and two G4 systems in Q3 2024, expanding spatial sequencing capabilities.
Presented new data at SITC conference, highlighting G4X's performance in various tissue types and single-cell immune profiling.
The company is focusing on completing G4X development, commercializing spatial biology services, and supporting G4 customers, while continuing to invest in R&D and commercial infrastructure.
A special committee is evaluating strategic alternatives, including a potential acquisition by Deerfield at $24.00 per share, with exclusivity granted for due diligence as of October 31, 2024.
Financial highlights
Q3 2024 revenue was $0.4M, down 12% year-over-year, mainly from consumables; nine-month revenue was $1.6M, down 13% from the prior year.
Net loss for Q3 2024 was $16.8M ($6.72 per share), improved from $22.4M ($9.25 per share) in Q3 2023; nine-month net loss was $63.1M.
Gross margin remained negative at $(0.3)M for Q3 and $(0.9)M for the nine months, impacted by low sales volume, rental placements, and high support costs.
Operating expenses decreased to $17.8M in Q3 2024 (down 27% YoY), including $2.2M in stock-based compensation and a $1.6M non-cash gain from lease modification.
Cash, cash equivalents, and short-term investments totaled $113.8M as of September 30, 2024.
Outlook and guidance
Operating expenses are expected to be slightly down in the near term but to increase longer term as investments in G4X, spatial biology, and commercial infrastructure continue.
The company expects continued significant losses and negative cash flows from operations for the foreseeable future.
Management believes current liquidity is sufficient to fund operations for at least 12 months from the report date.
Ongoing discussions regarding a potential strategic transaction; no earnings call held for Q3 2024.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Singular Genomics Systems
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Singular Genomics Systems Inc. is a life sciences technology company focused on developing next-generation sequencing (NGS) platforms and genomic analysis solutions. The company’s flagship products include the G4 Sequencing Platform, designed to deliver fast, accurate, and flexible sequencing for research and clinical applications. Singular Genomics aims to support areas such as oncology, immunology, and inherited disease research. Singular Genomics is headquartered in San Diego, California, and its shares are listed on the NASDAQ.